Inhibition of cholinergic signaling causes apoptosis in human bronchioalveolar carcinoma

Cancer Research

Volumn 73, Issue 4, 2013, Pages 1328-1339

  Lau, Jamie K ^a   Brown, Kathleen C ^a   Thornhill, Brent A ^a   Crabtree, Clayton M ^a,b   Dom, Aaron M ^a   Witte, Theodore R ^b   Hardman, W Elaine ^b   McNees, Christopher A ^a   Stover, Cody A ^a   Carpenter, A Betts ^a   Luo, Haitao ^c   Chen, Yi C ^c   Shiflett, Brandon S ^a   Dasgupta, Piyali ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Departments of Physiology   (United States)

^c Alderson Broaddus College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; BUNGAROTOXIN RECEPTOR; CASPASE 3; CHOLINE ACETYLTRANSFERASE; CHOLINE TRANSPORTER 1; CHOLINERGIC RECEPTOR; EPIDERMAL GROWTH FACTOR; MEMBRANE PROTEIN; NICOTINE; NICOTINIC RECEPTOR ALPHA3BETA2; NICOTINIC RECEPTOR BETA3; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN B; UNCLASSIFIED DRUG; VESAMICOL; VESICULAR ACETYLCHOLINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CHOLINERGIC ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LUNG ALVEOLUS CELL CARCINOMA; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEUROMUSCULAR DEPOLARIZING AGENTS; PHOSPHORYLATION; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874296019     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3190     Document Type: Article

References (48)

1. Levy BP, Drilon A, Makarian L, Patel AA, Grossbard ML. Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target? Oncology (Williston Park) 2010;24:888-98, 900.
2. Saintigny P, Wistuba II, Kim ES. Bronchioloalveolar carcinoma: a translational perspective. Oncology (Williston Park) 2010;24: 907-8, 14.
3. Colby TV, Noguchi M, Henschke C, Vazquez MF, Geisinger K, Yokose T, et al. Adenocarcinoma. In:Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, et al., editors. World health classification of tumours pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004. p. 35-44.
4. Ebbert JO, Chhatwani L, Aubry MC, Wampfler J, Stoddard S, Zhang F, et al. Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. J Thorac Oncol 2010;5:1213-20.
5. The Health Consequences of Smoking. A report of the Surgeon General's Office on Smoking and Health, DHHS, Washington DC. 2004.
6. Cancer IARC. IARC Monographs on the evaluation of carcinogenic risks to humans. In: Tobacco smoke and involuntary smoking. Lyon, France: IARC; 2004. p. 51-1187.
7. Garfield D. Mucinous and nonmucinous bronchioloalveolar carcinoma and smoking. Am J Clin Pathol 2010;133:341-2.
8. Boffetta P, Jayaprakash V, Yang P, Asomaning K, Muscat JE, Schwartz AG, et al. Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case-control studies in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control 2011;22:73-9.
9. Rolen KA, Fulton JPT, D. J., Strauss GM. Bronchoalveolar carcinoma (BAC) of the lung is related to cigarette smoking: a case-control study from Rhode Island (RI). Proc Am Soc Clin Oncol 22: 2003 (abstr 2711).
10. Morabia A, Wynder EL. Relation of bronchioloalveolar carcinoma to tobacco. BMJ 1992;304:541-3.
11. Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, et al. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol 2009;131:478-89.
12. Singh S, Pillai S, Chellappan S. Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J Oncol 2011;2011:456743.
13. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 2006; 103:6332-7.
14. Song P, Spindel ER. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J Pharmacol Sci 2008;106: 180-5.
15. Song P, Sekhon HS, Fu XW, Maier M, Jia Y, Duan J, et al. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res 2008;68:4693-700.
16. Song P, Sekhon HS, Jia Y, Keller JA, Blusztajn JK, Mark GP, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 2003;63:214-21. (Pubitemid 36070442)
17. Song P, Sekhon HS, Proskocil B, Blusztajn JK, Mark GP, Spindel ER. Synthesis of acetylcholine by lung cancer. Life Sci 2003;72: 2159-68. (Pubitemid 36300804)
18. Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 2007;67: 3936-44. (Pubitemid 46762183)
19. Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, et al. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst 2011;103:317-33.
20. Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, et al. MG624, an alpha7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis 2012;15:99-114.
21. Brown KC, Witte TR, Hardman WE, Luo H, Chen YC, Carpenter AB, et al. Capsaicin displays anti-proliferative activity against human small cell lung cancer in cell culture and nude mice models via the E2F pathway. PLoS One 2010;5:e10243.
22. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24: 148-54. (Pubitemid 19163397)
23. Shabbir M, Thompson CS, Mikhailidis D, Morgan RJ, Burnstock G. Extracellular ATP attenuates the growth of hormone refractory prostate cancer in vivo. Eur Urol Suppl 2003;2:24-7.
24. Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, et al. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Res 2008;68:3810-8.
25. Schafer MK, Weihe E, Erickson JD, Eiden LE. Human and monkey cholinergic neurons visualized in paraffin-embedded tissues by immunoreactivity for VAChT, the vesicular acetylcholine transporter. J Mol Neurosci 1995;6:225-35.
26. Tayebati SK, Tomassoni D, Di Stefano A, Sozio P, Cerasa LS, Amenta F. Effect of choline-containing phospholipids on brain cholinergic transporters in the rat. J Neurol Sci 2011;302:49-57.
27. Papka RE, Traurig HH, Schemann M, Collins J, Copelin T, Wilson K. Cholinergic neurons of the pelvic autonomic ganglia and uterus of the female rat: distribution of axons and presence of muscarinic receptors. Cell Tissue Res 1999;296:293-305. (Pubitemid 29219181)
28. Takahara Y, Maeda M, Nakatani T, Kiyama H. Transient suppression of the vesicular acetylcholine transporter in urinary bladder pathways following spinal cord injury. Brain Res 2007;1137:20-8.
29. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001;7:833-9.
30. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ II. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 2009;122:1-8.
31. Siegfried JM. Detection of human lung epithelial cell growth factors produced by a lung carcinoma cell line: use in culture of primary solid lung tumors. Cancer Res 1987;47:2903-10. (Pubitemid 17113434)
32. Domingo G, Perez CA, Velez M, Cudris J, Raez LE, Santos ES. EGF receptor in lung cancer: a successful story of targeted therapy. Expert Rev Anticancer Ther 2010;10:1577-87.
33. Linnerth NM, Baldwin M, Campbell C, Brown M, McGowan H, Moorehead RA. IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells. Oncogene 2005;24:7310-9.
34. Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer 2009;10:262-72.
35. Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008;3:815-8.
36. Bahr BA, Parsons SM. Acetylcholine transport and drug inhibition kinetics in Torpedo synaptic vesicles. J Neurochem 1986;46:1214-8.
37. Wilke RA, Mehta RP, Lupardus PJ, Chen Y, Ruoho AE, Jackson MB. Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells. J Biol Chem 1999;274: 18387-92.
38. Efange SM, Mach RH, Smith CR, Khare AB, Foulon C, Akella SK, et al. Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. Biochem Pharmacol 1995;49: 791-7.
39. Johnson BE. Tobacco and lung cancer. Prim Care 1998;25:279-91.
40. Johnson BE, Cortazar P, Chute JP. Second lung cancers in patients successfully treated for lung cancer. Semin Oncol 1997;24:492-9.
41. Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck BE Jr., Ihde DC, et al. Smoking abstinence and small cell lung cancer survival. An association. JAMA 1980;244:2175-9.
42. Ogawa K, Shiba K, Akhter N, Yoshimoto M, Washiyama K, Kinuya S, et al. Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy. Cancer Sci 2009;100:2188-92.
43. Ogawa K, Kanbara H, Shiba K, Kitamura Y, Kozaka T, Kiwada T, et al. Development and evaluation of a novel radioiodinated vesamicol analog as a sigma receptor imaging agent. EJNMMI Res 2012;2:54.
44. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003;111:81-90. (Pubitemid 36134851)
45. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 30-kinase/Akt pathway in vitro and in vivo. Cancer Res 2004;64:446-51. (Pubitemid 38120880)
46. Kitazaki T, Soda H, Doi S, Nakano H, Nakamura Y, Kohno S. Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. Lung Cancer 2005;50:19-24. (Pubitemid 41297465)
47. Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, et al. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. Mol Cancer Res 2009;7: 1378-89.
48. Denlinger CE, Rundall BK, Jones DR. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo. J Thorac Cardiovasc Surg 2005;130:1422-9.